Virios Therapeutics

Virios Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative antiviral therapies for diseases associated with virus-triggered abnormal immune responses, such as fibromyalgia (FM). It is hypothesized that an overactive immune response linked to the activation of tissue-resident herpes simplex virus-1 (HSV-1) may be a potential underlying cause of chronic conditions like FM, irritable bowel syndrome (IBS), chronic fatigue syndrome (CFS), and functional somatic syndromes, all of which are characterized by fluctuating disease patterns.The company is led by an executive team with extensive experience in successfully developing FM therapies. Its lead candidate drug, IMC-1, has been granted Fast Track designation by the FDA.